The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer

Ovarian cancer is the 5th leading cause of cancer death among women in the United States. The mevalonate pathway is thought to be a potential oncogenic pathway in the pathogenesis of ovarian cancer. Simvastatin, a 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) inhibitor, is a widely used drug for...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Stine, Jessica E., Guo, Hui, Sheng, Xiugui, Han, Xiaoyun, Schointuch, Monica N., Gilliam, Timothy P., Gehrig, Paola A., Zhou, Chunxiao, Bae-Jump, Victoria L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2015
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4808044/
https://ncbi.nlm.nih.gov/pubmed/26503475
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk